Tara Sands
Nurse Practitioner · Council Bluffs, IANPI 1992035778
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 29.8% of the total. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$301
- Amgen$294
- AstraZeneca$272
- Pfizer$243
- Aimmune Therapeutics, Inc.$220
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,08098%
- Education$692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,149 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $95,499 |
| EliquisApixaban | 70 | $77,613 |
| OzempicSemaglutide | 55 | $65,217 |
| TrulicityDulaglutide | 52 | $51,929 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $43,914 |
| JardianceEmpagliflozin | 32 | $35,963 |
| XareltoRivaroxaban | 18 | $20,175 |
| FarxigaDapagliflozin Propanediol | 19 | $20,115 |
| LinzessLinaclotide | 25 | $19,199 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,715 |
| JanuviaSitagliptin Phosphate | 17 | $13,029 |
| TrintellixVortioxetine Hydrobromide | 15 | $11,748 |
| Spiriva RespimatTiotropium Bromide | 14 | $8,630 |
| Repatha SyringeEvolocumab | 17 | $7,455 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $7,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $76 | $147,428138 claims |
| PfizerEliquis | $243 | $77,61370 claims |
| Novo NordiskOzempic | $301 | $65,21755 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $38 | $51,12260 claims |
| GSKTrelegy Ellipta | $12 | $43,91432 claims |
| AbbVieLinzess, Namzaric, Synthroid | $1,237 | $28,01753 claims |
| Johnson & JohnsonXarelto | $125 | $20,17518 claims |
| AstraZenecaFarxiga | $272 | $20,11519 claims |
| MerckJanuvia | $25 | $13,02917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $64 | $11,74815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Council Bluffs
- Marcella SorrellCouncil Bluffs$7K
- Lauren WarnekeCouncil Bluffs$3K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.